Table 1

. Characteristics of the cohort according to treatment type, KPNC 2000–2009 (n = 2,412)

No diabetes medicationMetformin-onlyMetformin plus other
Characteristics(n = 1,578)(n = 457)(n = 377)
Age at baseline, y
 40–4954 (3.4)27 (5.9)33 (8.8)
 50–54164 (10.4)71 (15.5)79 (21.0)
 55–59199 (12.6)83 (18.2)80 (21.2)
 60–64289 (18.3)94 (20.6)72 (19.1)
 65–69322 (20.4)74 (16.2)64 (17.0)
 70–74318 (20.2)73 (16.0)32 (8.5)
 75+232 (14.7)35 (7.7)17 (4.5)
Sex
 Female575 (36.4)178 (38.9)149 (39.5)
 Male1,003 (63.6)279 (61.1)228 (60.5)
Race/ethnicity
 Non-Hispanic white943 (59.8)253 (55.4)222 (58.9)
 Hispanic199 (12.6)64 (14.0)57 (15.1)
 Black112 (7.1)33 (7.2)16 (4.2)
 Asian/Pacific Islander216 (13.7)76 (16.6)48 (12.7)
 Othera108 (6.8)31 (6.8)34 (9.0)
BMI closest to baseline exam
 <25.0208 (13.2)42 (9.2)30 (8.0)
 25.0–29.9484 (30.7)109 (23.9)76 (20.2)
 30+801 (50.8)279 (61.1)252 (66.8)
 Unknown85 (5.4)27 (5.9)19 (5.0)
Indication for repeat exam
 Surveillance844 (53.5)279 (61.1)206 (54.6)
 Diagnostic734 (46.5)178 (38.9)171 (45.4)
Recurrent adenoma
 No839 (53.2)261 (57.1)195 (51.7)
 Any739 (46.8)196 (42.9)182 (48.3)
Mean HbA1c, mean (SD; n = 2,293)6.18 (0.59)6.73 (0.72)7.35 (0.88)
Time to repeat exam, median (IQR)4.1 (2.4)4.9 (2.5)5.2 (2.6)
  • aOther race/ethnicity includes Native American, multiracial/other, and unknown.